TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical-stage biotechnology company focused on RNA-based therapeutics for cancer, has published peer-reviewed findings in the journal Cancers showing that its lead candidate, TTX-MC138, improved survival in a preclinical model of breast cancer bone metastasis. The study demonstrated that systemically administered TTX-MC138 accumulated in metastatic bone lesions, reduced expression of microRNA-10b (miR-10b), and increased expression of the downstream tumor-suppressor gene HOXD10, leading to significant survival benefits compared to controls. Importantly, repeated dosing was well tolerated with no observed systemic toxicity.
These results are particularly significant because bone metastasis is a common and devastating complication of advanced breast cancer, often leading to skeletal-related events and poor prognosis. The findings suggest that targeting miR-10b, a well-documented biomarker of metastasis, could offer a novel therapeutic strategy for patients with metastatic disease. The study’s success also validates TransCode’s proprietary oligonucleotide nanotechnology platform, which enables targeted delivery of therapeutic agents to metastatic lesions.
Dr. William S. Marshall, Chief Scientific Officer of TransCode, commented, “The observed survival benefit and tolerability of TTX-MC138 in this challenging model are very encouraging. They provide further evidence that miR-10b inhibition has the potential to address unmet needs in metastatic cancer, where treatment options are often limited.” He added that the results support advancing TTX-MC138 toward clinical development.
The publication in Cancers adds to a growing body of evidence supporting TransCode’s approach. The company is developing a pipeline of first-in-class therapeutic candidates designed to harness the immune system and RNA interference to fight high-risk and advanced cancers. TTX-MC138, its lead candidate, is specifically aimed at metastatic tumors that overexpress miR-10b, a unique biomarker linked to cancer spread.
The implications of this research extend beyond breast cancer. Because miR-10b is implicated in multiple metastatic cancers, TTX-MC138 could have broad applicability across various tumor types. If these preclinical findings translate to humans, TTX-MC138 might offer a new option for patients with metastatic disease, potentially improving outcomes and quality of life.
For investors and the biotechnology industry, this news underscores the progress being made in RNA-based therapeutics, a field that has gained momentum with the success of mRNA vaccines. TransCode’s innovative approach to targeting metastasis-specific microRNAs could represent a significant advancement in cancer treatment paradigms.
More details about the study and its findings can be found in the full press release at https://ibn.fm/E6gbq. For the latest updates on TransCode Therapeutics, visit the company’s newsroom at https://ibn.fm/RNAZ.
